
Some breast cancer patients may benefit from the RESILIENCE clinical trial
RESILIENCE has expanded the spectrum of patients who can enter its clinical trial. Thus, those people with breast cancer being treated with anthracyclines who meet the criteria assessed by their oncologists may be eligible to participate in the trial. The remote ischemic conditioning (RIC) to which these cancer patients will







